MedCo's PCSK9 challenger steals the show at ESC with winning data

Whatever remaining doubts around The Medicines Company’s longer-lasting PCSK9 cholesterol fighter should be largely cleared by now, as the company posts first pivotal phase 3 data that show its inclisiran is at least as safe and effective as the two marketed drugs, Repatha and Praluent.